CCND1 is an inclusion criterion in 42 clinical trials for mantle cell lymphoma, of which 36 are open and 6 are closed. Of the trials that contain CCND1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (6 open), 7 are phase 1/phase 2 (7 open), 21 are phase 2 (19 open), and 3 are phase 3 (3 open) [4].

Ibrutinib has evidence of efficacy in patients with CCND1 mutation in mantle cell lymphoma [4].

Ibrutinib has evidence of efficacy in patients with CCND1 mutation in mature B-cell lymphoma/leukemia [4].

CCND1 is an inclusion criterion in 12 clinical trials for malignant solid tumor, of which 11 are open and 1 is closed. Of the trials that contain CCND1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 10 are phase 2 (9 open) [4].

CCND1 is an inclusion criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain CCND1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 2 are phase 3 (2 open) [4].

CCND1 is an inclusion criterion in 8 clinical trials for follicular lymphoma, of which 5 are open and 3 are closed. Of the trials that contain CCND1 status and follicular lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 7 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 3 are closed. Of the trials that contain CCND1 status and diffuse large B-cell lymphoma as inclusion criteria, 5 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 4 are open and 2 are closed. Of the trials that contain CCND1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain CCND1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain CCND1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 status and bladder carcinoma as inclusion criteria, 3 are phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 status and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 3 clinical trials for transformed non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and transformed non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for grade 3b follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain CCND1 status and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1 (1 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and malignant glioma as inclusion criteria, 2 are early phase 1 (2 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCND1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 2 clinical trials for waldenstrom macroglobulinemia, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for grade 1 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and grade 1 follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for grade 2 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and grade 2 follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for grade 3 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and grade 3 follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and Richter syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].

CCND1 is an inclusion criterion in 1 clinical trial for T-cell/histiocyte-rich large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].